Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL23537554 | 0.87 | PTGS1 (0.35) | PTGS1PTGS2MAPTALDH1A1NPC1 | |
| SCHEMBL166734 | 0.86 | ALDH1A1 (0.41) | PTGS1PTGS2MAPTALDH1A1NPC1 | |
| SCHEMBL110074 | 0.84 | NPSR1 (0.44) | MAPTALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL31729190 | 0.83 | PTGS1 (0.39) | PTGS1PTGS2MAPTALDH1A1NPC1 | |
| SCHEMBL14524709 | 0.83 | PTGS1 (0.39) | PTGS1PTGS2MAPTALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL15206614 | 0.83 | SMN1; SMN2 (0.42) | MAPTALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL654797 | 0.79 | LMNA (0.44) | PTGS1PTGS2MAPTALDH1A1NPC1 | |
| SCHEMBL16398391 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1NPSR1HTT | |
| SCHEMBL17619238 | 0.78 | MAPT (0.33) | MAPTALDH1A1NPC1MAPK1POLB | |
| SCHEMBL22411350 | 0.77 | KMT2A (0.47) | MAPTALDH1A1NPC1NPSR1XBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3938340-B1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEV LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024183806-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2024-09-12 | — | — | WO | disclosed |
| CN-118290350-A | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| WO-2006087530-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | PTGS1 101/4885PTGS2 133/4885MAPT 4330/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | PTGS1 399/4885PTGS2 169/4885MAPT 4733/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | PTGS1 102/4885PTGS2 120/4885MAPT 4391/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | PTGS1 518/4885PTGS2 1444/4885MAPT 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.